Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can you point out solid timelines.
Here is what I seen!
As a result of a delay in delivery of the Toxicity report to the African hospitals, GOMA, PRC, and Panzi Hospital, Bukavu, DRC, the administration of the ITV-1 immunotherapy initial injections into the HIV/AIDS-infected volunteers was delayed. We expect that to commence soon.
ENZC has provided SAGA with its draft of the Business Combination Agreement and related documents and is awaiting any edits or comments in anticipation of a final version being circulated for signature by October 31, 2023.
Most OTC have lost their luster the past few years. I would much rather have share of a $11 Nasdaq stock than a 4 cent OTC. All I can say is for those that don’t like the deal are how things are progressing they can always sell and move on or do like many of us do while we wait and take advantage of the dips and runs.
I’m shocked that anyone would not want the saga deal to happen, unless of course if we got a deal with a BP like Samsung or Regen. How long have many been waiting for that to happen?
How is ENZC suppose to make anything happen without the money that Saga will provide? Shareholders have been waiting for years on a deal that will get the ball rolling and when we get one many balk. It’s easier for a nasdaq stock like saga or Regen to run big once the money moves the products than it is for a broke otc to move big without a BP deal.
I for one am looking forward to a deal getting finalized. In the mean time I will take advantage of the dips and Runs.
Good Luck and Happy Trading!
The company don’t get to make up dividend distribution rules! On a better note!
https://finance.yahoo.com/news/biogenysis-international-patent-application-covering-120000543.html
Administration of the patented immunotherapy ITV-1 treatment to volunteers under a fast-track protocol supervised by Neuro Pharma Ltd - Rwanda, at HEAL Africa Hospitals, GOMA, PRC and Panzi Hospital, Bukavu, DRC.
As I stated With a special dividend usually you have to buy ENZC before the pay date and hold it until one business after the payday.
To capture a dividend a shareholder must buy the shares prior to the ex-dividend date
The biggest difference concerning special dividend stocks is that the ex-dividend (for special payouts) comes after the record and pay date, not before (like is the case with regular dividends or smaller special dividends).
https://www.dividend.com/dividend-education/special-dividends-everything-investors-need-to-know/
More explanations
https://www.thebluecollarinvestor.com/ex-dividend-dates-rules-for-standard-and-special-dividends/
Let’s hope you are wrong Maga. I use to be excited to see your post but You have been super negative since the fall from .13+
Which was on the 250 million dollar deal annnoncement with saga before it got increased to 450 million. Which anyone that bought the low .002’s to 5’s or better before it ran on that 1st saga deal and traded it could have made nice bank$$$.
I don’t understand the change in others thought process. I see ENZC as a winner but hey Any otc that has fluctuated like this one can make winners out of anyone that buys extra shares on the dips and trades at least part of the extra shares on the ripping Runs. IMO! Good Luck and Happy Trading.
Here s whatI read
An issuer should reflect the conversion in its financial statements only once the conversion has settled and the rights under the preferred stock have been extinguished. In certain circumstances, there may be additional accounting required between exercise and settlement of the conversion option.
An issuer should reflect the conversion in its financial statements only once the conversion has settled and the rights under the preferred stock have been extinguished. In certain circumstances, there may be additional accounting required between exercise and settlement of the conversion option.
When registration with the SEC is not required, publicly traded companies must still make information publicly available pursuant to Rule 10b-5 under the Securities Exchange Act of 1934 and pursuant to Rule 144(c)(2) under the Securities Act of 1933. OTCMarkets offers the Alternative Reporting Standard for companies who provide material information publicly to investors.
Try looking here
https://www.investopedia.com/terms/r/rule10b5.asp
Several adjustments to the use of the affirmative defense doctrine by insiders became effective on Feb. 27, 2023. Insider trading under these rules means there is a plan to sell securities by officers, directors, and others with access to MNPI.
Rule 10b5-1(c)(1)—Mandatory Cooling-Off Period
For directors and Section 16 officers wishing to trade their company’s stock, there is now a mandatory cooling-off period. Section 16 is a rule within the Securities Exchange Act of 1934 that spells out the regulatory filing responsibilities that directors, officers, and principal stockholders are legally required to adhere to.
The new required cooling-off period covers the later of: 90 days before trading under a 10b5-1 plan can be activated, or two business days after disclosure in a periodic report of the issuer’s financial results for the quarter in which the plan was adopted.
The Bottom Line
Rule 10b5-1 allows insiders to sell company stock by setting up a predetermined plan that specifies in advance the share price, amount, and transaction date. The insider selling the stock and the broker carrying out the transaction must certify that they are not aware of any material nonpublic information (MNPI).
The 8/18/23 otc update proves it did not happened during that period.
What’s with all the worry?
Also we should see a filing if they sell.
https://www.investopedia.com/terms/f/form4.asp
Securities transactions by officers, directors and 10%+ ...
investmentfundlawblog.com
https://www.investmentfundlawblog.com › resources
Section 16 of the 1934 Act requires a public company's officers, directors and holders of more than 10% of any class of equity security to report their ...
I think we agree on how to play ENZC. We can all agree to disagree on many things like hedgefunds, MM’s/Brokers playing games and naked shorting it’s a proven Fact with many FInra Fines to prove it the few times they get caught..
ENZC News Out?
Some flip a lot more than 100k regularly. This has been the perfect stock for buying extra shares on the dips and flipping part of them for profits or until you’re riding for Free while waiting on another Kaboom! IMO!
Although the profit percentage has been lower lately. I jumped on that low 3 wagon last weeks for extra shares and now we are pushing the 4’s again.
Sold some more of my flipping shares the last few days. Hoping for a dip to load more extra shares before the next Run, but I had rather see a nice run back to .10 or better again first. These 5% to 25% beer money moves are harder to play.
But hey 25% x 4 good flips could equal another free ride.
Good Luck and Happy Trading!
The Bottom Line
Rule 10b5-1 allows insiders to sell company stock by setting up a predetermined plan that specifies in advance the share price, amount, and transaction date. The insider selling the stock and the broker carrying out the transaction must certify that they are not aware of any material nonpublic information (MNPI).
https://www.investopedia.com/terms/r/rule-10b5-1.asp
Please point out where this article exempts them!
Here is what I see in your article.
When registration with the SEC is not required, publicly traded companies must still make information publicly available pursuant to Rule 10b-5 under the Securities Exchange Act of 1934 and pursuant to Rule 144(c)(2) under the Securities Act of 1933. OTCMarkets offers the Alternative Reporting Standard for companies who provide material information publicly to investors.
Try looking here
https://www.investopedia.com/terms/r/rule10b5.asp
Several adjustments to the use of the affirmative defense doctrine by insiders became effective on Feb. 27, 2023. Insider trading under these rules means there is a plan to sell securities by officers, directors, and others with access to MNPI.
Rule 10b5-1(c)(1)—Mandatory Cooling-Off Period
For directors and Section 16 officers wishing to trade their company’s stock, there is now a mandatory cooling-off period. Section 16 is a rule within the Securities Exchange Act of 1934 that spells out the regulatory filing responsibilities that directors, officers, and principal stockholders are legally required to adhere to.
The new required cooling-off period covers the later of: 90 days before trading under a 10b5-1 plan can be activated, or two business days after disclosure in a periodic report of the issuer’s financial results for the quarter in which the plan was adopted.
The Bottom Line
Rule 10b5-1 allows insiders to sell company stock by setting up a predetermined plan that specifies in advance the share price, amount, and transaction date. The insider selling the stock and the broker carrying out the transaction must certify that they are not aware of any material nonpublic information (MNPI).
SEC filings are important regulatory documents required of all public companies to provide key information to investors or potential investors. The public can review SEC filings by visiting the commission's online database, EDGAR.
The federal securities laws require certain individuals (such as officers, directors, and those that hold more than 10% of any class of a company's securities, together we'll call, “insiders”) to report purchases, sales, and holdings of their company's securities by filing Forms 3, 4, and 5.
Form 4 is required to be filed by a company or the individual at the company when there is a change in the holdings of company insiders. Form 4 must be filed with the SEC within two days of the transaction.
https://www.investopedia.com/terms/f/form4.asp
Who is required to file Form 4?
Form 4 is required to be filed by a company or the individual at the company when there is a change in the holdings of company insiders. Form 4 must be filed with the SEC within two days of the transaction.
Securities transactions by officers, directors and 10%+ ...
investmentfundlawblog.com
https://www.investmentfundlawblog.com › resources
Section 16 of the 1934 Act requires a public company's officers, directors and holders of more than 10% of any class of equity security to report their ...
Ownership Reports and Trading by Officers, Directors ...
SEC.gov
https://www.sec.gov › rules › 2002/08 › ownership-re...
In each case, a reporting person must report the transaction on Form 4 before the end of the second business day following the deemed date of execution, as ...
https://www.sec.gov/rules/2002/08/ownership-reports-and-trading-officers-directors-and-principal-security-holders
The otc O/S was just updated few days ago. They are not dumping
Outstanding Shares
3,010,804,133
Updated 08/18/2023
https://www.otcmarkets.com/stock/ENZC/security
Nice Beer money day 10% x 10 is 100%
100% = possibility to ride for Free!
For Traders they Got to love trading days like today!
Locked and loaded with plenty of shares and banked profits.
Now Ready for the next dip or Run!
How do we know if it’s them or who it is that provides the pipe money?
Sagaliam expects to raise additional capital through private investment in public equities ("PIPE"). The anticipated capital raise from the PIPE is expected to be primarily used by VIRO to pay transaction-related expenses and fund the clinical trials of it anti-HIV therapeutic ITV-1, complete the African Project and advance marketing of IPF Immune™.
The funds are to be used by BGEN to complete the production of and test species-specific monoclonal antibodies (mAbs) for treating COVID-19, HIV, and Feline Leukemia. The funding will significantly enhance BGEN's drug discovery capabilities using its proprietary, cutting-edge Artificial Intelligence (AI) technology and enlarge its IP portfolio while also expanding the AI platform's capabilities to advance health care from that based on reactive disease care to P4 medicine, namely care that is predictive, preventive, personalized and participatory.
https://www.otcmarkets.com/stock/ENZC/news/Enzolytics-Inc-Reports-Amendment-to-Non-Binding-Term-Sheet-with-the-Special-Purpose-Acquisition-Company-Sagaliam-Acquisi?id=406065
Well Stuckholder not really sorry to hear ya trapped at the bottom, after seeing the bitterness towards smart traders shining thru, smart investors made a pile when it ran from .25 to $50 a few years ago. when it was a BP.
There was plenty of signs to get out in the big bucks when they did not follow thru.
Hell even KOO’s was smart enough to sell in the $13 to $25 range.
There is filings to back that up!
Did not have to be a genius to figure that out.
Got to know when to fold em. Again sorry for stockholders who can’t read the signs.
Every dog has its day. If one can trade on expert market they could have made up to 499000% after the big drop.
It’s all about the timing. Even most Stuckholders can figure that out. Some Rookies may never learn or have to learn the hard way. Stuckholder bitterness shining thru.
Looks like I may have jumped a bit early this evening
Buy 70,000 Limit $0.0331 Day
$0.0326 3:28 PM 08/18/2023 3:28 PM 08/18/2023 0.031 0.0325 0.032
ENZC
ENZOLYTICS INC
Filled
Buy 100,000 Limit $0.0341 GTC
Exp 02/13/2024
- 3:23 PM 08/18/2023
That’s alright still a nice adding point IMO!
I got to admit CC’s lack of communication or straight forward understandable PR’s is a big problem and frustrating, but keep in mind the once 250 now 450 million dollar saga deal if and when it closes should do the trick at least for traders. If one don’t like the dips but don’t want to sell and go away, they could always do like many other smart traders here that don’t complain on every dip, but instead add or double down. Then take some profits on every ripping Run with at least part of their extra double down share.
Wash, Rinse and Repeat until there at least Riding for Free.
No PM. Sorry to hear ya trapped at the bottom us smart investors made a pile when it ran from .25 to $50 a few years ago. when it was a BP.
There was plenty of signs to get out in the big bucks when they did not follow thru.
Hell even KOO’s was smart enough to sell in the $13 to $25 range.
Did not have to be a genius to figure that out.
Got to know when to fold em. Again sorry for loser who can’t read the signs.
Every dog has its day. If one can trade on expert market they could have made up to 499000% today to help with any big loss.
Looks like about 49,900% gain today so far!
Read away! Plenty more proof can be googled. Here’s some of the latest.
https://finance.yahoo.com/news/virogentics-inc-receives-permit-export-170000224.html
https://finance.yahoo.com/news/virogentics-inc-provides-african-project-133000736.html
https://finance.yahoo.com/news/correction-source-virogentics-announces-approval-180000087.html
https://finance.yahoo.com/news/virogentics-inc-introduce-dietary-supplement-125500411.html
https://finance.yahoo.com/news/biogenysis-inc-announces-collaboration-khalpey-110000575.html
https://finance.yahoo.com/news/enzolytics-inc-files-supplemental-information-140500704.html
We EXPECT the ... SAME RESULTS as the BULGARIAN TRIALS
Patients were Stage II, III and late stage IV! Go ENZC
The prior clinical trial showed an 80% drop in viral load, an increase in CD4+ cell counts as well as an increase in other key immune cells. CD4+ cells are the cells that are infected by HIV and are eventually depleted by the virus. So the increase in CD4 count is key. For instance, this could include dendritic cells, macrophages, monocytes, and helper T cells. And in line with the improved cell counts were improvements in opportunistic infections, compatibility with other ART (antiretroviral therapy) drugs, and no side effects.
The big difference to keep in mind is that all the currently marketed drugs use chemotherapy versus immunotherapy. None of the current drugs help restore the immune system. They simply block the viral replication inside the immune cells.
LoL! They said it would start in August!
It looks like they have everything in place for August.
What’s the problem!
The impatient should move on if they don’t like the process!
I believe they will deliver. Ready to celebrate the start of the trials this month.
Got the wine.
Needs some cheese!
I think some are confusing the African trial which is supposed to start this month with the EMA trial which is supposed to begin late 2023 early 2024.
The results of this African pilot clinical trial which is supposed to start this month will be used in the development of the European Medicine Authority (EMA) clinical trials expected to begin in late 2023/early 2024.
Once they announce the start of the August trial. I think it will make it clear for those who are confused.
Once they get or if they get EMA approval I hear it will be a whole lot easier and quicker to get FDA Approval.
That’s right they announced they got the Approval of Final Protocol from the Dept for HIV and AIDS, Ministry of Health of the DRC July 24th for the African pilot clinical trial.
the protocol criteria was the final step necessary to meet the requirements to inject the African HIV/Aids volunteer patients, subject to the review and approval of the ethics committee of the Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-AFRICA).
This paves the way for the projected August administration of the patented immunotherapy ITV-1 treatment to volunteers under a fast-track protocol supervised by Neuro Pharma Ltd - Rwanda, at HEAL Africa Hospitals, GOMA, PRC and Panzi Hospital, Bukavu, DRC.
https://money.tmx.com/quote/ENZC:US/news/5888749613694750/CORRECTION_FROM_SOURCE_Virogentics_Announces_Approval_of_Final_Protocol_from_the_Dept_for_HIV_and_AIDS_Ministry_of_Health_of_the_DRC
I think some are confusing the African trial with the EMA trial which want begin until late 2023 early 2024
Virogentics, Inc. ("VIRO") a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced today the receipt of an export permit for the delivery of the treatments to be administered to the volunteer HIV/AIDS patients at the HEAL Africa Hospitals, GOMA, PRC and Panzi Hospital, Bukavu, DRC. The results of this African pilot clinical trial will be used in the development of the European Medicine Authority (EMA) clinical trials expected to begin in late 2023/early 2024
These appear to be 2 different trials!
In addition to the EMA, VIRO's African project is progressing in August with the initial administration of ITV-1 to HIV/AIDS infected volunteers at the HEAL Africa Hospitals, GOMA, PRC and Panzi Hospital, Bukavu, DRC under the supervision of Neuro Pharma Ltd - Rwanda."
Virogentics, Inc. ("VIRO") a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced today the receipt of an export permit for the delivery of the treatments to be administered to the volunteer HIV/AIDS patients at the HEAL Africa Hospitals, GOMA, PRC and Panzi Hospital, Bukavu, DRC. The results of this African pilot clinical trial will be used in the development of the European Medicine Authority (EMA) clinical trials expected to begin in late 2023/early 2024.
Great it looks like that was the last step.
In addition to the EMA, VIRO's African project is progressing in August with the initial administration of ITV-1 to HIV/AIDS infected volunteers at the HEAL Africa Hospitals, GOMA, PRC and Panzi Hospital, Bukavu, DRC under the supervision of Neuro Pharma Ltd - Rwanda."
Virogentics, Inc. ("VIRO") a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced today the receipt of an export permit for the delivery of the treatments to be administered to the volunteer HIV/AIDS patients at the HEAL Africa Hospitals, GOMA, PRC and Panzi Hospital, Bukavu, DRC. The results of this African pilot clinical trial will be used in the development of the European Medicine Authority (EMA) clinical trials expected to begin in late 2023/early 2024.
Why ask when most everyone knows anyone can buy into saga by buying it.
SAGA closed at $10.90 today
Will they announce it or wait until it’s finished?
https://money.tmx.com/quote/ENZC:US/news/5888749613694750/CORRECTION_FROM_SOURCE_Virogentics_Announces_Approval_of_Final_Protocol_from_the_Dept_for_HIV_and_AIDS_Ministry_of_Health_of_the_DRC
Saga pays who 57k every time they file an extension?
https://quantisnow.com/insight/4586166
Looks like they got thru the last step! Let the trails begin!
https://money.tmx.com/quote/ENZC:US/news/5888749613694750/CORRECTION_FROM_SOURCE_Virogentics_Announces_Approval_of_Final_Protocol_from_the_Dept_for_HIV_and_AIDS_Ministry_of_Health_of_the_DRC
So approval by DRC!
Now it looks like we wait for the review and approval of the ethics committee of the Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-AFRICA).
How many hoops or pockets to pad does ENZC have to jump through.
So how do you explain this?
The parent company ENZC and its other subsidiary RobustoMed, Inc. (“RBMD”) are not part of the transaction.
4.As additional terms and events regarding the transaction take place, the Company will disclose them through additional press releases.
So will there be other subsidiary spin offs post dividend payout?
https://enzolytics.com/company-news/